EFFICACY OF MIRIKIZUMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY

被引:0
|
作者
Sandborn, William J.
Ferrante, Marc
Bhandari, Raj
D'Haens, Geert
Berliba, Elina
Feagan, Brian G.
Klekotka, Paul
Laskowski, Janelle
Durante, Michael
Tuttle, Jay L.
Naegeli, April
机构
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P033
引用
收藏
页码:S23 / S23
页数:1
相关论文
共 50 条
  • [31] ADALIMUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE FOR 52 WEEKS IN PATIENTS WITH ULCERATIVE COLITIS
    Sandborn, W. J.
    Van Assche, G.
    Thakkar, R. B.
    Lazar, A.
    Kron, M.
    Yang, M.
    Patel, S. P.
    Chao, J.
    Mulani, P. M.
    GUT, 2012, 61 : A400 - A401
  • [32] Quality of Life in patients with Marfan syndrome included in a randomised controlled double-blind trial
    De Nobele, S.
    Loeys, B.
    De Paepe, A.
    De Backer, J.
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2011, 10 : S17 - S17
  • [33] Adalimumab Improves Health-Related Quality of Life for 52 Weeks in Patients With Ulcerative Colitis
    Sandborn, William J.
    Van Assche, Gert A.
    Thakkar, Roopal
    Lazar, Andreas
    Kron, Martina
    Yang, Mei
    Chao, Jingdong
    Mulani, Parvez
    GASTROENTEROLOGY, 2011, 140 (05) : S263 - S263
  • [34] Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis
    Sandborn, William J.
    Ferrante, Marc
    Bhandari, Bal R.
    Berliba, Elina
    Hibi, Toshifumi
    D'Haens, Geert R.
    Tuttle, Jay L.
    Krueger, Kathryn
    Friedrich, Stuart
    Durante, Michael
    Arora, Vipin
    Naegeli, April N.
    Schmitz, Jochen
    Feagan, Brian G.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (01) : 105 - +
  • [35] Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
    Vermeire, Severine
    Lakatos, Peter L.
    Ritter, Timothy
    Hanauer, Stephen
    Bressler, Brian
    Khanna, Reena
    Isaacs, Kim
    Shah, Saumin
    Kadva, Alysha
    Tyrrell, Helen
    Oh, Young S.
    Tole, Swati
    Chai, Akiko
    Pulley, Jennifer
    Eden, Christopher
    Zhang, Wenhui
    Feagan, Brian G.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (01): : 28 - 37
  • [36] Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial
    Sands, Bruce E.
    Panaccione, Remo
    D'Haens, Geert
    Schreiber, Stefan
    Jairath, Vipul
    Duvall, Aaron
    Kierkus, Jaroslaw
    Walczak, Michael
    Naik, Snehal
    Gilder, Kye
    Lindstrom, Beatriz
    Ogilvie, Kathleen
    Sandborn, William J.
    Vermeire, Severine
    Rubin, David
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 210 - 221
  • [37] Efficacy of aceclofenac and celecoxib on functioning and health-related quality of life (QOL) in patients with knee osteoarthritis (OA): A 6-week double-blind, placebo controlled, randomized study
    Guillemin, F
    Emery, P
    Kvien, TK
    Stucki, G
    Pavesi, M
    Fortea, J
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 489 - 489
  • [39] The impact of biological interventions for ulcerative colitis on health-related quality of life
    LeBlanc, Katie
    Mosli, Mahmoud H.
    Parker, Claire E.
    MacDonald, John K.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09):
  • [40] Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide
    McCaffrey, Nikki
    Asser, Tegan
    Fazekas, Belinda
    Muircroft, Wendy
    Agar, Meera
    Clark, Katherine
    Eckermann, Simon
    Lee, Jessica
    Joshi, Rohit
    Allcroft, Peter
    Sheehan, Caitlin
    Currow, David C.
    BMC CANCER, 2020, 20 (01)